{"id":2415,"date":"2026-02-27T14:28:20","date_gmt":"2026-02-27T22:28:20","guid":{"rendered":"https:\/\/puny-toaster.flywheelstaging.com\/?p=2415"},"modified":"2026-09-19T20:28:53","modified_gmt":"2026-09-20T03:28:53","slug":"avisi-technologies-announces-10-7m-capital-raise-to-advance-novel-glaucoma-device-development","status":"publish","type":"post","link":"https:\/\/avisitech.com\/ja\/avisi-technologies-announces-10-7m-capital-raise-to-advance-novel-glaucoma-device-development\/","title":{"rendered":"Avisi Technologies Announces\u00a0$10.7M\u00a0Capital\u00a0Raise\u00a0to Advance\u00a0Novel Glaucoma\u00a0Device\u00a0Development\u00a0"},"content":{"rendered":"<ul>\n<li aria-setsize=\"-1\" data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"2\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:[8226],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;hybridMultilevel&quot;}\" data-aria-posinset=\"1\" data-aria-level=\"1\"><i><span data-contrast=\"none\">Avisi Technologies\u00a0announces\u00a0Series A financing\u00a0for\u00a0SAPPHIRE pivotal trial\u00a0of\u00a0<\/span><\/i><span data-contrast=\"none\">VisiPlate<\/span><span data-contrast=\"none\">\u00ae<\/span><i><span data-contrast=\"none\">\u00a0novel glaucoma treatment\u00a0<\/span><\/i><span data-ccp-props=\"{&quot;335559739&quot;:192}\">\u00a0<\/span><\/li>\n<\/ul>\n<ul>\n<li aria-setsize=\"-1\" data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"2\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:[8226],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;hybridMultilevel&quot;}\" data-aria-posinset=\"2\" data-aria-level=\"1\"><i><span data-contrast=\"none\">Round led by\u00a0MedVenture\u00a0Partners with participation from new investors and existing investors<\/span><\/i><span data-ccp-props=\"{&quot;335559739&quot;:192}\">\u00a0<\/span><\/li>\n<\/ul>\n<ul>\n<li aria-setsize=\"-1\" data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"2\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:[8226],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;hybridMultilevel&quot;}\" data-aria-posinset=\"3\" data-aria-level=\"1\"><i><span data-contrast=\"none\">VisiPlate<\/span><\/i><i><span data-contrast=\"none\">\u00ae<\/span><\/i><i><span data-contrast=\"none\">\u00a0shunt\u00a0features\u00a0unique\u00a0design\u00a0with\u00a0a\u00a0novel metamaterial, thinner than a human hair\u00a0<\/span><\/i><span data-ccp-props=\"{&quot;335559739&quot;:192}\">\u00a0<\/span><\/li>\n<\/ul>\n<p><span data-contrast=\"none\">Redwood City, CA \u2013 February 25, 2026 \u00a0\u2013\u00a0\/<a href=\"https:\/\/www.prnewswire.com\/news-releases\/avisi-technologies-announces-10-7m-capital-ra[\u2026]to-advance-novel-glaucoma-device-development-302696957.html\">PR Newswire<\/a>\/ Avisi Technologies, Inc., an ophthalmic medical device company advancing novel, sight-saving technologies, announces the closing of $10.7M in new financing. T<\/span><span data-contrast=\"auto\">he\u00a0Series A\u00a0round was led by\u00a0MedVenture\u00a0Partners, with participation\u00a0from\u00a0new investors Sherpa Healthcare Partners, SNBL-Gemseki, SBI US Gateway Fund, Golden Seeds,\u00a0and\u00a0OneOneFive. This financing\u00a0round had\u00a0strong participation from existing investors,\u00a0including Good Growth Capital,\u00a0Accanto\u00a0Partners, Life Sciences Greenhouse Investment, and Quaker Capital Investments.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559738&quot;:240,&quot;335559739&quot;:240,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">The\u00a0funding will support the\u00a0company\u2019s\u00a0pivotal clinical\u00a0trial\u00a0SAPPHIRE,\u00a0which received\u00a0<\/span><a href=\"https:\/\/avisitech.com\/ja\/avisi-technologies-investigational-device-exemption-for-visiplate-approved-by-fda\/\"><i><span data-contrast=\"none\">FDA\u00a0IDE\u00a0approval<\/span><\/i><\/a><span data-contrast=\"auto\">\u00a0\u00a0in\u00a02025,\u00a0and\u00a0further development\u00a0of\u00a0Avisi&#8217;s pipeline\u00a0which includes novel treatments\u00a0addressing\u00a0the entire spectrum of glaucomatous disease.\u00a0The\u00a0SAPPHIRE Trial is\u00a0designed to evaluate the safety and efficacy of\u00a0<\/span><span data-contrast=\"none\">VisiPlate<\/span><span data-contrast=\"none\">\u00ae<\/span><span data-contrast=\"auto\">\u00a0<\/span><span data-contrast=\"auto\">\u2013\u00a0a novel glaucoma treatment device engineered to sustainably reduce intraocular pressure (IOP) by improving\u00a0outflow of\u00a0aqueous.\u00a0As part of the\u00a0Series A\u00a0financing,\u00a0Justin Fukuyama,\u00a0MS, MBA,\u00a0a\u00a0Partner at\u00a0MedVenture\u00a0Partners,\u00a0joins\u00a0the company\u2019s\u00a0Board of\u00a0Directors.\u00a0<\/span><span data-contrast=\"none\">\u201cGlaucoma continues to impose a tremendous burden on patients and healthcare systems,\u201d\u00a0Justin Fukuyama\u00a0commented,\u00a0\u201cThe\u00a0VisiPlate<\/span><span data-contrast=\"none\">\u00ae<\/span><span data-contrast=\"none\">\u00a0device addresses a critical gap in patient care, and we are proud to partner with the team at\u00a0Avisi\u00a0Technologies\u00a0to advance this novel treatment into the clinic.&#8221;<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559738&quot;:240,&quot;335559739&quot;:240,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">&#8220;Avisi Technologies\u2019\u00a0innovative\u00a0meta-materials and design\u00a0engineering\u00a0tackles the unmet needs of\u00a0glaucoma patients,&#8221; said\u00a0Darren Cai, PhD, MBA,\u00a0Managing\u00a0Partner at\u00a0Sherpa\u00a0Healthcare\u00a0Partners.\u00a0&#8220;VisiPlate\u2019s\u00a0unique materials,\u00a0ultra-thin\u00a0profile, and multichannel\u00a0design,\u00a0has\u00a0the potential to redefine treatment, maintain healthy eye pressures,\u00a0and\u00a0improve outcomes for patients facing limited options.&#8221;<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">The\u00a0VisiPlate<\/span><span data-contrast=\"none\">\u00ae<\/span><span data-contrast=\"none\">\u00a0device is designed with multiple and redundant microchannels to provide sustained aqueous flow while minimizing the risk of blockage and re-intervention. The device is made of ultrathin, biocompatible materials that\u00a0seek\u00a0to avoid longstanding reasons for failure of existing glaucoma treatment options.\u00a0VisiPlate<\/span><span data-contrast=\"none\">\u00ae<\/span><span data-contrast=\"none\">\u00a0has been previously studied in the VITA Trial with long-term follow up data presented at the 2026\u00a0American\u00a0Glaucoma\u00a0Society\u00a0Annual Meeting.\u00a0The\u00a0SAPPHIRE trial is currently enrolling, with multiple sites open across the US.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">Avisi\u2019s\u00a0Founder and\u00a0CEO, Rui Jing Jiang, said\u00a0&#8220;Avisi&#8217;s successful capital raise is\u00a0a\u00a0testament\u00a0to the strong data, steady momentum, and\u00a0expert\u00a0team behind the\u00a0VisiPlate<\/span><span data-contrast=\"none\">\u00ae<\/span><span data-contrast=\"none\">\u00a0technology. We look forward to\u00a0partnering with our\u00a0world-class investors and clinicians to execute a successful\u00a0pivotal trial and bring novel, vision-saving technologies to\u00a0glaucoma\u00a0patients worldwide.\u201d<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n<p><b><span data-contrast=\"none\">About\u00a0VisiPlate<\/span><\/b><b><span data-contrast=\"none\">\u00ae<\/span><\/b><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">Avisi Technologies&#8217;\u00a0<\/span><a href=\"https:\/\/avisitech.com\/ja\/visiplate\/\"><b><span data-contrast=\"none\">VisiPlate<\/span><\/b><b><span data-contrast=\"none\">\u00ae<\/span><\/b><\/a><b><span data-contrast=\"none\">\u00a0<\/span><\/b><span data-contrast=\"none\">aqueous shunt is a unique device made of a patented metamaterial that has been designed to be non-fibrotic and is many times thinner than\u00a0a human\u00a0hair. The device is both doctor and patient-centric, designed for ease of implantation, longevity, comfort, and aesthetics. Its multiple, redundant microchannels are engineered to provide sustained aqueous flow while minimizing the risk of blockage and re-intervention, both\u00a0common challenges\u00a0with currently available glaucoma surgical solutions.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n<p><b><span data-contrast=\"none\">About Glaucoma\u00a0and Current Treatment<\/span><\/b><span data-ccp-props=\"{&quot;134233117&quot;:true,&quot;134233118&quot;:true,&quot;201341983&quot;:0,&quot;335559740&quot;:278}\">\u00a0<\/span><\/p>\n<p><a href=\"https:\/\/avisitech.com\/ja\/what-is-glaucoma-ja\/\"><b><span data-contrast=\"none\">Glaucoma<\/span><\/b><\/a><span data-contrast=\"none\">\u00a0is\u00a0the leading cause of irreversible blindness worldwide, affecting over 133 million people according to Market Scope\u2019s 2025 Glaucoma Surgical Device Market Report, and currently has no cure. In glaucoma patients, excess fluid\u00a0builds up\u00a0within the eye, increasing pressure on the optic\u00a0nerve\u00a0and leading to permanent vision loss. Glaucoma is a group of diseases, the most common of which are open-angle glaucoma (OAG) and angle-closure\u00a0glaucoma.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:true,&quot;134233118&quot;:true,&quot;201341983&quot;:0,&quot;335559740&quot;:278}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">OAG often has no early warning signs or symptoms. It occurs when the\u00a0eye&#8217;s\u00a0drainage system (trabecular meshwork) becomes clogged, preventing normal fluid outflow and leading to elevated eye pressure. Without diagnosis and treatment, OAG can cause gradual vision loss over time. Current treatments for glaucoma include medications, lasers, surgeries, and medical device solutions. However, these interventions rely on patient compliance, re-treatment, or may fail due to occlusion and scarring over time. There\u00a0remains\u00a0a pressing need for safe and effective long-term treatments for glaucoma that improve patient outcomes and quality of life.\u00a0<\/span><span data-ccp-props=\"{&quot;134233117&quot;:true,&quot;134233118&quot;:true,&quot;201341983&quot;:0,&quot;335557856&quot;:16777215,&quot;335559740&quot;:278}\">\u00a0<\/span><\/p>\n<p><b><span data-contrast=\"none\">About Avisi Technologies<\/span><\/b><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><a href=\"https:\/\/avisitech.com\/ja\/\"><b><span data-contrast=\"none\">Avisi Technologies<\/span><\/b><\/a><span data-contrast=\"none\">\u00a0is a clinical-stage medical device company committed to advancing vision care through innovative ophthalmic solutions. The company&#8217;s portfolio includes\u00a0state-of-the-art\u00a0treatments for glaucoma and other ocular conditions. These include its flagship\u00a0VisiPlate<\/span><span data-contrast=\"none\">\u00ae<\/span><span data-contrast=\"none\">\u00a0aqueous shunt, V-001 sustained intraocular drug-delivery platform, and the\u00a0VisiPlate-S drainage device for treating\u00a0mild to moderate\u00a0glaucoma at the time of cataract surgery. Avisi has been recognized and supported by\u00a0numerous\u00a0organizations, including the National Science Foundation (NSF), the Glaucoma Research Foundation, SXSW, Johnson &amp; Johnson JLABs, Medtech Innovator Accelerator, UCSF Rosenman Institute, and the University of Pennsylvania, among others. Avisi is funded by venture capital investors, angel investors, and scientific research grants. For more information, visit\u00a0<\/span><a href=\"https:\/\/avisitech.com\/ja\/\"><b><span data-contrast=\"none\">avisitech.com<\/span><\/b><\/a><span data-contrast=\"none\">.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">VisiPlate<\/span><span data-contrast=\"none\">\u00ae<\/span><span data-contrast=\"none\">\u00a0is an investigational device. The\u00a0VisiPlate<\/span><span data-contrast=\"none\">\u00ae<\/span><span data-contrast=\"none\">\u00a0device is for investigational use only, and\u00a0not\u00a0yet available for sale.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335557856&quot;:16777215,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n<p><b><i><span data-contrast=\"none\">Media Contact:<\/span><\/i><\/b><span data-ccp-props=\"{&quot;134233118&quot;:false,&quot;201341983&quot;:0,&quot;335557856&quot;:16777215,&quot;335559739&quot;:0,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n<p><i><span data-contrast=\"none\">Seth Harrington<\/span><\/i><span data-ccp-props=\"{&quot;134233118&quot;:false,&quot;201341983&quot;:0,&quot;335557856&quot;:16777215,&quot;335559739&quot;:0,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n<p><a href=\"mailto:info@avisitech.com\"><b><i><span data-contrast=\"none\">info@avisitech.com<\/span><\/i><\/b><\/a><br \/>\n<span data-contrast=\"none\">More information on the\u00a0<\/span><a href=\"https:\/\/avisitech.com\/clinical-trials-at-avisi-technologies\/\"><span data-contrast=\"none\">SAPPHIRE<\/span><\/a><span data-contrast=\"none\">\u00a0clinical trial<\/span><span data-ccp-props=\"{&quot;134233118&quot;:false,&quot;201341983&quot;:0,&quot;335557856&quot;:16777215,&quot;335559739&quot;:0,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">SOURCE: Avisi Technologies, Inc.<\/span><span data-ccp-props=\"{&quot;134233118&quot;:false,&quot;201341983&quot;:0,&quot;335557856&quot;:16777215,&quot;335559739&quot;:0,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Avisi Technologies\u00a0announces\u00a0Series A financing\u00a0for\u00a0SAPPHIRE pivotal trial\u00a0of\u00a0VisiPlate\u00ae\u00a0novel glaucoma treatm [&hellip;]<\/p>\n","protected":false},"author":486,"featured_media":2133,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[150],"tags":[],"class_list":["post-2415","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Avisi Technologies Announces\u00a0$10.7M\u00a0Capital\u00a0Raise\u00a0to Advance\u00a0Novel Glaucoma\u00a0Device\u00a0Development\u00a0 - Avisi Technologies Inc.<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/avisitech.com\/ja\/avisi-technologies-announces-10-7m-capital-raise-to-advance-novel-glaucoma-device-development\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Avisi Technologies Announces\u00a0$10.7M\u00a0Capital\u00a0Raise\u00a0to Advance\u00a0Novel Glaucoma\u00a0Device\u00a0Development\u00a0 - Avisi Technologies Inc.\" \/>\n<meta property=\"og:description\" content=\"Avisi Technologies\u00a0announces\u00a0Series A financing\u00a0for\u00a0SAPPHIRE pivotal trial\u00a0of\u00a0VisiPlate\u00ae\u00a0novel glaucoma treatm [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/avisitech.com\/ja\/avisi-technologies-announces-10-7m-capital-raise-to-advance-novel-glaucoma-device-development\/\" \/>\n<meta property=\"og:site_name\" content=\"Avisi Technologies Inc.\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-27T22:28:20+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-20T03:28:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/avisitech.com\/wp-content\/uploads\/2026\/03\/7.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1257\" \/>\n\t<meta property=\"og:image:height\" content=\"839\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"ivankornienko\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"ivankornienko\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"4\u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/avisi-technologies-announces-10-7m-capital-raise-to-advance-novel-glaucoma-device-development\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/avisi-technologies-announces-10-7m-capital-raise-to-advance-novel-glaucoma-device-development\\\/\"},\"author\":{\"name\":\"ivankornienko\",\"@id\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/#\\\/schema\\\/person\\\/8912f5bbc34efc0fee96277c64d105a5\"},\"headline\":\"Avisi Technologies Announces\u00a0$10.7M\u00a0Capital\u00a0Raise\u00a0to Advance\u00a0Novel Glaucoma\u00a0Device\u00a0Development\u00a0\",\"datePublished\":\"2026-02-27T22:28:20+00:00\",\"dateModified\":\"2026-09-20T03:28:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/avisi-technologies-announces-10-7m-capital-raise-to-advance-novel-glaucoma-device-development\\\/\"},\"wordCount\":848,\"publisher\":{\"@id\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/avisi-technologies-announces-10-7m-capital-raise-to-advance-novel-glaucoma-device-development\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/avisitech.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/7.webp\",\"articleSection\":[\"News\"],\"inLanguage\":\"ja\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/avisi-technologies-announces-10-7m-capital-raise-to-advance-novel-glaucoma-device-development\\\/\",\"url\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/avisi-technologies-announces-10-7m-capital-raise-to-advance-novel-glaucoma-device-development\\\/\",\"name\":\"Avisi Technologies Announces\u00a0$10.7M\u00a0Capital\u00a0Raise\u00a0to Advance\u00a0Novel Glaucoma\u00a0Device\u00a0Development\u00a0 - Avisi Technologies Inc.\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/avisi-technologies-announces-10-7m-capital-raise-to-advance-novel-glaucoma-device-development\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/avisi-technologies-announces-10-7m-capital-raise-to-advance-novel-glaucoma-device-development\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/avisitech.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/7.webp\",\"datePublished\":\"2026-02-27T22:28:20+00:00\",\"dateModified\":\"2026-09-20T03:28:53+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/avisi-technologies-announces-10-7m-capital-raise-to-advance-novel-glaucoma-device-development\\\/#breadcrumb\"},\"inLanguage\":\"ja\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/avisitech.com\\\/ja\\\/avisi-technologies-announces-10-7m-capital-raise-to-advance-novel-glaucoma-device-development\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/avisi-technologies-announces-10-7m-capital-raise-to-advance-novel-glaucoma-device-development\\\/#primaryimage\",\"url\":\"https:\\\/\\\/avisitech.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/7.webp\",\"contentUrl\":\"https:\\\/\\\/avisitech.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/7.webp\",\"width\":1257,\"height\":839,\"caption\":\"Avisi Technologies Announces $10.7M Capital Raise to Advance Novel Glaucoma Device Development\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/avisi-technologies-announces-10-7m-capital-raise-to-advance-novel-glaucoma-device-development\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Avisi Technologies Announces\u00a0$10.7M\u00a0Capital\u00a0Raise\u00a0to Advance\u00a0Novel Glaucoma\u00a0Device\u00a0Development\u00a0\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/#website\",\"url\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/\",\"name\":\"Avisi Technologies Inc.\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ja\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/#organization\",\"name\":\"Avisi Technologies Inc.\",\"url\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/avisitech.com\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/Avisi-Technologies-Logo-SVG-Final-1.svg\",\"contentUrl\":\"https:\\\/\\\/avisitech.com\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/Avisi-Technologies-Logo-SVG-Final-1.svg\",\"width\":124,\"height\":43,\"caption\":\"Avisi Technologies Inc.\"},\"image\":{\"@id\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/#\\\/schema\\\/person\\\/8912f5bbc34efc0fee96277c64d105a5\",\"name\":\"ivankornienko\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/302018db4e1d52c0124450ceca39d595309c13b7907918bd1357932b410ecc81?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/302018db4e1d52c0124450ceca39d595309c13b7907918bd1357932b410ecc81?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/302018db4e1d52c0124450ceca39d595309c13b7907918bd1357932b410ecc81?s=96&d=mm&r=g\",\"caption\":\"ivankornienko\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Avisi Technologies Announces\u00a0$10.7M\u00a0Capital\u00a0Raise\u00a0to Advance\u00a0Novel Glaucoma\u00a0Device\u00a0Development\u00a0 - Avisi Technologies Inc.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/avisitech.com\/ja\/avisi-technologies-announces-10-7m-capital-raise-to-advance-novel-glaucoma-device-development\/","og_locale":"ja_JP","og_type":"article","og_title":"Avisi Technologies Announces\u00a0$10.7M\u00a0Capital\u00a0Raise\u00a0to Advance\u00a0Novel Glaucoma\u00a0Device\u00a0Development\u00a0 - Avisi Technologies Inc.","og_description":"Avisi Technologies\u00a0announces\u00a0Series A financing\u00a0for\u00a0SAPPHIRE pivotal trial\u00a0of\u00a0VisiPlate\u00ae\u00a0novel glaucoma treatm [&hellip;]","og_url":"https:\/\/avisitech.com\/ja\/avisi-technologies-announces-10-7m-capital-raise-to-advance-novel-glaucoma-device-development\/","og_site_name":"Avisi Technologies Inc.","article_published_time":"2026-02-27T22:28:20+00:00","article_modified_time":"2026-09-20T03:28:53+00:00","og_image":[{"width":1257,"height":839,"url":"https:\/\/avisitech.com\/wp-content\/uploads\/2026\/03\/7.webp","type":"image\/webp"}],"author":"ivankornienko","twitter_card":"summary_large_image","twitter_misc":{"\u57f7\u7b46\u8005":"ivankornienko","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"4\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/avisitech.com\/ja\/avisi-technologies-announces-10-7m-capital-raise-to-advance-novel-glaucoma-device-development\/#article","isPartOf":{"@id":"https:\/\/avisitech.com\/ja\/avisi-technologies-announces-10-7m-capital-raise-to-advance-novel-glaucoma-device-development\/"},"author":{"name":"ivankornienko","@id":"https:\/\/avisitech.com\/ja\/#\/schema\/person\/8912f5bbc34efc0fee96277c64d105a5"},"headline":"Avisi Technologies Announces\u00a0$10.7M\u00a0Capital\u00a0Raise\u00a0to Advance\u00a0Novel Glaucoma\u00a0Device\u00a0Development\u00a0","datePublished":"2026-02-27T22:28:20+00:00","dateModified":"2026-09-20T03:28:53+00:00","mainEntityOfPage":{"@id":"https:\/\/avisitech.com\/ja\/avisi-technologies-announces-10-7m-capital-raise-to-advance-novel-glaucoma-device-development\/"},"wordCount":848,"publisher":{"@id":"https:\/\/avisitech.com\/ja\/#organization"},"image":{"@id":"https:\/\/avisitech.com\/ja\/avisi-technologies-announces-10-7m-capital-raise-to-advance-novel-glaucoma-device-development\/#primaryimage"},"thumbnailUrl":"https:\/\/avisitech.com\/wp-content\/uploads\/2026\/03\/7.webp","articleSection":["News"],"inLanguage":"ja"},{"@type":"WebPage","@id":"https:\/\/avisitech.com\/ja\/avisi-technologies-announces-10-7m-capital-raise-to-advance-novel-glaucoma-device-development\/","url":"https:\/\/avisitech.com\/ja\/avisi-technologies-announces-10-7m-capital-raise-to-advance-novel-glaucoma-device-development\/","name":"Avisi Technologies Announces\u00a0$10.7M\u00a0Capital\u00a0Raise\u00a0to Advance\u00a0Novel Glaucoma\u00a0Device\u00a0Development\u00a0 - Avisi Technologies Inc.","isPartOf":{"@id":"https:\/\/avisitech.com\/ja\/#website"},"primaryImageOfPage":{"@id":"https:\/\/avisitech.com\/ja\/avisi-technologies-announces-10-7m-capital-raise-to-advance-novel-glaucoma-device-development\/#primaryimage"},"image":{"@id":"https:\/\/avisitech.com\/ja\/avisi-technologies-announces-10-7m-capital-raise-to-advance-novel-glaucoma-device-development\/#primaryimage"},"thumbnailUrl":"https:\/\/avisitech.com\/wp-content\/uploads\/2026\/03\/7.webp","datePublished":"2026-02-27T22:28:20+00:00","dateModified":"2026-09-20T03:28:53+00:00","breadcrumb":{"@id":"https:\/\/avisitech.com\/ja\/avisi-technologies-announces-10-7m-capital-raise-to-advance-novel-glaucoma-device-development\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/avisitech.com\/ja\/avisi-technologies-announces-10-7m-capital-raise-to-advance-novel-glaucoma-device-development\/"]}]},{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/avisitech.com\/ja\/avisi-technologies-announces-10-7m-capital-raise-to-advance-novel-glaucoma-device-development\/#primaryimage","url":"https:\/\/avisitech.com\/wp-content\/uploads\/2026\/03\/7.webp","contentUrl":"https:\/\/avisitech.com\/wp-content\/uploads\/2026\/03\/7.webp","width":1257,"height":839,"caption":"Avisi Technologies Announces $10.7M Capital Raise to Advance Novel Glaucoma Device Development"},{"@type":"BreadcrumbList","@id":"https:\/\/avisitech.com\/ja\/avisi-technologies-announces-10-7m-capital-raise-to-advance-novel-glaucoma-device-development\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/avisitech.com\/ja\/"},{"@type":"ListItem","position":2,"name":"Avisi Technologies Announces\u00a0$10.7M\u00a0Capital\u00a0Raise\u00a0to Advance\u00a0Novel Glaucoma\u00a0Device\u00a0Development\u00a0"}]},{"@type":"WebSite","@id":"https:\/\/avisitech.com\/ja\/#website","url":"https:\/\/avisitech.com\/ja\/","name":"Avisi Technologies Inc.","description":"","publisher":{"@id":"https:\/\/avisitech.com\/ja\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/avisitech.com\/ja\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Organization","@id":"https:\/\/avisitech.com\/ja\/#organization","name":"Avisi Technologies Inc.","url":"https:\/\/avisitech.com\/ja\/","logo":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/avisitech.com\/ja\/#\/schema\/logo\/image\/","url":"https:\/\/avisitech.com\/wp-content\/uploads\/2024\/01\/Avisi-Technologies-Logo-SVG-Final-1.svg","contentUrl":"https:\/\/avisitech.com\/wp-content\/uploads\/2024\/01\/Avisi-Technologies-Logo-SVG-Final-1.svg","width":124,"height":43,"caption":"Avisi Technologies Inc."},"image":{"@id":"https:\/\/avisitech.com\/ja\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/avisitech.com\/ja\/#\/schema\/person\/8912f5bbc34efc0fee96277c64d105a5","name":"ivankornienko","image":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/secure.gravatar.com\/avatar\/302018db4e1d52c0124450ceca39d595309c13b7907918bd1357932b410ecc81?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/302018db4e1d52c0124450ceca39d595309c13b7907918bd1357932b410ecc81?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/302018db4e1d52c0124450ceca39d595309c13b7907918bd1357932b410ecc81?s=96&d=mm&r=g","caption":"ivankornienko"}}]}},"_links":{"self":[{"href":"https:\/\/avisitech.com\/ja\/wp-json\/wp\/v2\/posts\/2415","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/avisitech.com\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/avisitech.com\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/avisitech.com\/ja\/wp-json\/wp\/v2\/users\/486"}],"replies":[{"embeddable":true,"href":"https:\/\/avisitech.com\/ja\/wp-json\/wp\/v2\/comments?post=2415"}],"version-history":[{"count":1,"href":"https:\/\/avisitech.com\/ja\/wp-json\/wp\/v2\/posts\/2415\/revisions"}],"predecessor-version":[{"id":2419,"href":"https:\/\/avisitech.com\/ja\/wp-json\/wp\/v2\/posts\/2415\/revisions\/2419"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/avisitech.com\/ja\/wp-json\/wp\/v2\/media\/2133"}],"wp:attachment":[{"href":"https:\/\/avisitech.com\/ja\/wp-json\/wp\/v2\/media?parent=2415"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/avisitech.com\/ja\/wp-json\/wp\/v2\/categories?post=2415"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/avisitech.com\/ja\/wp-json\/wp\/v2\/tags?post=2415"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}